--- title: "Drug Discovery CRO" canonical: "https://www.pharmalegacy.com/drug-discovery-cro/" lastmod: "2025-07-11T15:22:56+00:00" generator: "llm-mirrors/1.0.19" --- PharmaLegacy: Drug Discovery CRO Quickly identify hits and confidently optimize leads with PharmaLegacy’s range of high fidelity, high throughput in vitro assays. Accelerate Your Early-Stage Pipelines High fidelity assays performed to exacting standards are crucial for you to identify those rare, valuable compounds with the potential to ultimately win approval. PharmaLegacy has the assays and experience to screen your libraries and unearth the key insights that you need to find those winning compounds. Our highly experienced staff, rigorous assay validation, meticulous protocols, and ability to execute quickly make PharmaLegacy the partner of choice for pharmaceutical companies who can’t afford to compromise but still need to hold to a budget. Join 18 of the top 20 pharmaceutical companies. Optimize your pipelines efficiently and expeditiously with PharmaLegacy. Get access to proprietary, high-fidelity assays and accelerate your pipelines! Contact PharmaLegacy today. Our Drug Discovery Services Include: Kinase & Enzyme Assays BaF3 Cell based Kinase Activity Assays GPCR & Ion Channel Assays Cytotoxicity Cell-based Assays Cell-based Immune Modulator Assays Cell Based Immuno-Oncology Assays In Vitro Antibody-Drug Conjugate (ADC) Evaluation In Vitro Vaccine Evaluation FACS Assays In Vitro Safety Assays Biomarkers and Pharmacodynamics Analysis Over 400 kinases & enzymes available Custom assay development with full validation Many classes of kinases and enzymes covered: carboxylases, DNA polymerases, GTPases, Hydrolases, Nicotinamide kinases, Nucleotidases, Oxidases, Phosphatases, Phosphohydrolases, Phosphoribosyltransferases, Proteases, and more Epigenetics Targeted Assays: bromodomain-containing protein binding partner assays, histone acetyltransferase, histone lysine demethylase, histone methyltransferase, protein arginine methyltransferase Full suite of detection technologies: ADP-Glo, AhphaELISA, FI, FP, HTRF, TR-FRET, and more High-throughput, 384-well format MORE INFO ON KINASE / ENZYME ASSAYS More than 350 BaF3 engineering cell lines Multiple target WT and mutant cell lines Coverage of most kinase families Multiple readouts available (CTG, CCK8, MTT, LDH, and more) Customized cell line generation available HTS-compatible MORE INFO ON BA/F3 ASSAYS Extensive Cell Line Library: Choose from over 400 pre-characterized GPCR cell lines and more than 50 Ion Channel cell lines. All GPCR subtypes, including Gs, Gq, and Gi Tailored Cell Line Engineering using overexpression, knock out, knock in, knock down, mutation, and report gene integration. Complete cell line validation. High-Throughput Screening in a 384-well assay format Beta Arrestin assays using Nano-BRET/Nano Bit and Enzyme Fragment Complementation (EFC) GPCR internalization assays using HiBit MORE INFO ON GPCR ASSAYS Over 200 tumor cell lines available, encompassing a diverse range of cancers and genetic backgrounds Drug-resistant cell lines available 2D and 3D cell culture models available Diverse readout options available, including MTT, cck8, CTG, Brdu, and more Flexible treatment times, ranging from acute exposures to chronic dosing (up to 14 days) Combination drug testing High throughput screens, 96-well or 384-well MORE INFO ON CELL-BASED CYTOTOXICITY ASSAYS T Cell Stimulation / Inhibition Assay T Cell Proliferation Assay Splenocyte Stimulation Assay Macrophage / Whole Blood Stimulation Assay Pro-Inflammatory Stimulation Assay Mixed Lymphocyte Reaction (MLR) Assay Immunogenicity of Recombinant Proteins MORE INFO ON CELL-BASED IMMUNOMODULATOR ASSAYS Antibody-Dependent Cellular Cytotoxicity (ADCC) Antibody-Dependent Cellular Phagocytosis (ADCP) Complement-Dependent Cellular Cytotoxicity (CDC) T Cell Killing Assay CAR-T / TCR-T Cell Killing Assay CAR-T / TCR-T Safety Assay MORE INFO ON CELL BASED IMMUNO-ONCOLOGY ASSAYS Antibody Affinity Evaluation Antibody Internalization Assay ADC Cytotoxicity Assay Bystander Killing Assay ADCC and CDC Assay MORE INFO ON IN VITRO ADC EVALUATION Anti-Virus MRNA vaccine evaluation assays Dendritic cell (DC) vaccine production DC:T re-stimulation assay Immugenicity of neo-antigens Memory T cell subsets after immunization (flow cytometry evaluation) Cytokine expression in T Cell subsets (flow cytometry evaluation) Splenocyte stimulation assays (immunogenicity of IL-2 and IFN-gamma by ELISPOT or FACS) MORE INFO ON IN VITRO VACCINE EVALUATION Tumour-infiltrating lymphocytes (TILs) analysis Immune profiling assays Antigen binding assays Antigen block assays Cytokine / phospho-protein detection Cytometric bead array (CBA) assays Cell-based function assays (cell cycle, apoptosis, endocytosis, polarization, proliferation, differentiation) MORE INFO ON FACS ASSAYS hERG Assay Mitochondrial Toxicity (Glu/Gal) Assay Safety Panel (44/90 Panel). This panel screens a broad range of targets involved in drug toxicity in humans, including GPCRs (G-protein coupled receptors), ion channels, nuclear receptors, and transporters. MORE INFO ON IN VITRO SAFETY ASSAYS QPCR, Digital PCR and RNA-seq Multiplex cytokine measurement by MSD, Luminex, CBA or ELISA TIL (tumor-Infiltrating leukocyte) profiling by FACS: T cells, DCs, Macrophage, NK Monocytes, MDSC, etc MORE INFO ON BIOMARKERS & PHARMACODYNAMICS ANALYSIS Contact PharmaLegacy Today! ✕ Let PharmaLegacy provide the answers you need. The Experience to Deliver PharmaLegacy has supported over 600 IND applications. We have been trusted with critical studies by 18 of the top 20 pharmaceutical companies. Combined with the extensive experience of our scientific staff – over 15 years on average – PharmaLegacy is ready to fill your drug discovery pipelines with promising candidates. The Tools to Succeed With 380,000 square feet of facility space, the latest in high-throughput analytical equipment, and a plethora of extensively validated assays, PharmaLegacy is equipped to screen your libraries for all relevant hits and provide the deep, rich data you need to confidently choose your lead compounds. Take Your Pipeline Further When you are ready to move your lead compounds into preclinical development, stick with us. PharmaLegacy has over 1,500 animal models available immediately, including on-site non-human primate colonies. Our capacity for over 30,000 animals and models spanning over 100 indications give us the scale and throughput to quickly initiate and execute your studies. DRUG DISCOVERY DONE RIGHT Contact us today to accelerate your drug discovery. See for yourself how you can get world-class study execution using the latest technologies, on budget and with no delay. Your drug discovery is too important to compromise. Tell us your study needs and see for yourself why the clients who work with PharmaLegacy stay with PharmaLegacy.